Open access peer-reviewed chapter

A View of Platelets in Dengue

Written By

Tamiris Azamor da Costa Barros and Luzia Maria de-Oliveira-Pinto

Submitted: May 12th, 2017 Reviewed: December 12th, 2017 Published: March 7th, 2018

DOI: 10.5772/intechopen.73084

Chapter metrics overview

2,211 Chapter Downloads

View Full Metrics


Platelets were mainly associated with coagulation and hemostasis; however, other biological effects have been attributed to platelets, including angiogenesis, extracellular matrix synthesis, inflammation, and immune response. Dengue virus infection causes 200 million cases of severe flu-like illness annually, escalating to life-threatening hemorrhagic fever or shock syndrome. Some hypotheses are postulated for immunopathogenesis of dengue, including antibody enhancement theory, T-cell activation of cross-reactive memory, and original antigenic sin. All hypotheses, to some extent, induce an overproduction or a skewed profile of cytokine release, giving rise to the term cytokine storm/cytokine tsunami. Although thrombocytopenia is typical of both mild and severe diseases, the mechanism triggering platelet reduction is incompletely understood. In dengue, platelets are one of the major cell populations affected by direct and/or indirect mechanisms of infection. It is common to observe both thrombocytopenia and platelet dysfunction in dengue, both strongly related to the clinical outcome. Thus, platelets are frequently affected in dengue, either for alteration of their own functionality, for “silent transport” of virus, or as an anti-viral immune cell. In this way, we describe some of functional aspects of platelets on dengue, observing circulating mediators, intraplatelet proteins contents, morphology, activation markers, and ability to interact with dengue virus.


  • dengue
  • platelets
  • thrombocytopenia
  • dysfunction of platelets
  • immunopathogenesis

1. Introduction

As the first cellular components accumulate at sites where there is vascular wall damage, platelets rapidly initiate events such as aggregation, exocytosis of granule constituents, adhesion protein expression, cytokine, and others inflammatory mediator’s secretion and directly interact with endothelial cells and immune cells. In addition, they can perform the synthesis of new proteins through their complex post-transcription repertoire for post-activation translation, corroborating the existence of potential biological functions of platelets. In dengue, platelets are one of the major cell populations affected by direct and/or indirect mechanisms of infection.

1.1. An overview of immunopathogenesis of dengue

Dengue is one of the arboviruses transmitted by mosquitoes of the genus Aedes in a human-mosquito-human cycle. It is endemic in more than 120 countries, where 50 to 100 million infections occur each year, which correspond to 55% of the world population live at risk of infection. Therefore, dengue has the greatest impact on public health worldwide with higher morbidity, albeit fortunately with low mortality rate [1]. The etiologic agent is the dengue virus (DENV), which has four antigenically distinct viral serotypes, the DENV 1 to 4. DENVs share between 65 and 75% homology in their RNA sequences. As a member of the Flaviviridae family, the DENV consists of an envelope formed by a lipid bilayer derived from the endoplasmic reticulum of the host cell into which the envelope (E) and membrane (M) proteins are inserted. The viral particle is spherical in shape and approximately 50 nm in diameter. Below the viral envelope is a nucleocapsid composed of an icosahedral viral capsid formed by the capsid protein (C) and complexed to a single-stranded RNA molecule with positive polarity [2, 3]. Viral RNA DENV is approximately 10.7 Kb and is modified at its 5‘ end by the addition of the cap structure but is devoid of the poly-A tail at the 3’ end and has a single open reading frame encoding a protein precursor polyprotein viral infection. This precursor protein is cleaved by both host cell proteases and viral protease, yielding 10 proteins: structural C, pre-Membrane (prM)/ M, E, and nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The translated structural proteins are incorporated into the viral particles during their maturation, while the nonstructural proteins are involved in the replication and/ or assembly of the virions. The 3‘and 5’ noncoding regions are also important for viral replication [4, 5, 6].

Dengue fever is generally an acute disease, with a broad spectrum of clinical manifestations ranging from a clinically inapparent infection, an undifferentiated acute febrile illness, dengue fever (DF), to more severe forms, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The first symptoms of DF and DHF are indistinguishable, but DHF is associated with hemorrhagic manifestations, plasma extravasation, and thrombocytopenia (counts below 150,000 platelets/mm3). Thrombocytopenia is not necessarily restricted to severe forms of dengue, since it is possible to see small bleeding in mild infections. DSS is distinguished from DHF by the presence of cardiovascular or other organs impairment, which occurs when loss of plasma to interstitial spaces results in shock. In general, DSS is a serious disease, with mortality rates of up to 20%, but may also be less than 1% in places with sufficient resources and with clinical experience [7, 8]. Symptomatic disease typically follows three phases: an initial febrile phase lasting 3 to 7 days; a critical phase around the defervescence during which complications may appear in some patients; and a spontaneous recovery phase [9].

A simplified categorization for the classification of dengue severity was proposed by the World Health Organization (WHO) in 2009 in which DHF and DSS were grouped as severe dengue [1]. This classification was based on a multicenter study that treats the illness as a dynamic and systemic event. The new classification describes three sets of clinical signs and symptoms: (1) Dengue fever without signs of alarm (DF) characterized by nausea, vomiting, rash, myalgia, headache, arthralgia, and positive tourniquet test with no signs bleeding and leukopenia; (2) Dengue fever with warning signals (DFwWS) includes abdominal pain or tenderness, persistent vomiting, fluid accumulation, lethargy, agitation, hepatomegaly (increase > 2 cm), elevated serum transaminases, and decreased platelet count; and (3) Severe Dengue Fever characterized by severe plasma extravasation, leading to shock and fluid accumulation, accompanied by respiratory discomfort, severe bleeding, and involvement of organs such as the liver, central nervous system (with altered consciousness), heart, and other organs. This new classification proved to be more sensitive to the identification of severe forms, reducing the proportion of patients previously unclassifiable, which facilitated the clinical management of patients [10].

Briefly, immunopathogenesis of dengue is postulated by some hypotheses, including antibody enhancement theory [11, 12], T-cell activation of cross-reactive memory, and original antigenic sin [13]. All hypotheses, to some extent, induce an overproduction or a skewed profile of cytokine release, giving rise to the term cytokine storm/cytokine tsunami [14].

The humoral response is mainly directed to the prM, E, and NS1 proteins, whereas in the cases of secondary infection, the response against NS3 and NS5 is observed [15, 16]. It is believed that a primary infection can create effective, lasting protection against reinfection by the same serotype, but triggers short-term cross-protection against the other serotypes [17]. Neutralization of infection by specific antibodies may occur by inhibiting the entry of the virus through its specific receptors into the target cell [18] or by inhibiting viral fusion into the target cell cytoplasm [19]. On the other hand, epidemiological studies suggest that homologous immunity may increase the severity of the disease during a subsequent infection by a heterologous serotype [11]. It is believed that low neutralizing antibodies, those that induce cross-reaction, produced in response to a previous serotype, contribute to the pathogenesis of dengue by promoting the entry of the virus through Fcγ receptors into myeloid cells, a phenomenon known as antibody-dependent infection (ADE) [20].

The role of T cells during dengue infection is still controversial, with studies supporting either an immunoprotective or immunopathological role [21]. Pioneer studies proposed that T cells have a detrimental role during secondary dengue infections in a process termed “original antigenic sin.” Based on this theory, cross-reactive T cells generated during primary infection, which recognize secondary-infected DENV serotype with low affinity, are poorly functional but prone to inducing immunopathology [13]. Thus, as cross-reactive memory, T cells are present in increased numbers and have a low activation threshold. They may outcompete their naïve subsets that have high affinity for secondary-infected serotype with an overall detrimental outcome for protective immunity [22]. Collectively, studies showed that dengue infection elicits a broad-specific T cell response that peaks around day 8–10 from fever onset [23, 24]. Dengue-specific CD8+ T cells are present at higher frequencies compared to their CD4+ counterparts and preferentially target nonstructural proteins NS3, NS4b, and NS5, while CD4+ T cells are mainly directed toward the capsid envelope and the secreted protein NS1 [23].

Moreover, studies have demonstrated that high concentrations of circulating cytokines, mainly released by T cells, monocytes, macrophages, and endothelial cells from patients, would be involved in the pathogenesis of dengue [24]. Initially, antiviral mechanisms of innate immune response mediated by interferons (IFNs), mainly produced by dendritic cells (DCs), monocytes, macrophages, and natural killer (NKs) cells, are involved in initial infection control. The antiviral activity of type I IFNs (IFN-α/β) is initiated hours after infection and promotes inhibition of viral replication of infected cells, activation of the antiviral state by uninfected cells, and stimulation of the antiviral activity of the cells NK and CD8+ T lymphocytes [25, 26]. DENV proteins such as NS4B and NS5 have been shown to inhibit IFN-α/-β signaling [27, 28, 29]. However, in vitro and in vivo studies have demonstrated that DENV is capable of activating the production of IFN-α by human plasmacytoid dendritic cells (pDC) [30]. The IFN-γ (or IFN-type II), a cytokine involved with Th1 profile, is produced primarily by T lymphocytes, NK cells, and to a lesser extent by macrophages. The IFN-γ, like other IFNs, has an antiviral effect and promotes increased expression of human leukocyte antigen (HLA) class I and II molecules and stimulates antigen presenting and cytokine production by antigen-presenting cells (APCs) [31]. Kurane et al. reported higher levels of IFN-γ in the serum of patients with DHF and DF compared to healthy subjects, but IFN-γ levels were still higher after defervescence in patients with DHF. According to the authors, these results suggest that IFN-γ would play an important role in infection control; however, high levels of this cytokine after defervescence, together with increased T cell activation, would contribute to the pathogenesis of DHF [32]. TNF-α is another cytokine that appears to play an important role in dengue. TNF-α is produced by mononuclear phagocytes, neutrophils, lymphocytes, and NK cells. The interaction of TNF-α and endothelial cells promotes induction of adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin (E-CD62), being strongly involved in vascular damage, septic shock, and anti-tumor immunity [31]. In dengue, TNF-α appears to be involved in vascular damage, and authors observed an increased permeability and morphological changes in endothelial cells treated in vitro with TNF-α [33]. Studies have shown elevated plasmatic cytokines in dengue, such as IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, and IL-18, transforming growth factor-beta-receptor (TGF-β) [34, 35, 36, 37, 38, 39, 40]. Chaturvedi et al. reported that DF patients had higher levels of IFN-γ and IL-2, whereas the majority of DHF patients had IL-4, IL-6, and IL-10 elevation, on the 4th and 8th days of the disease, coinciding with the defervescence phase [41]. Pretreatment of monocytes/macrophages with Th2 profile cytokines (IL-4 or IL-13) increased the susceptibility of these cells to DENV infection [42]. Plasma levels of IL-10 were correlated with thrombocytopenia in dengue patients [34, 43]. High production of TNF-α, IL-1β, IL-12, IL-17, soluble IL-1 receptor type 1 protein (sST2), and tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL), as well as apoptosis in DENV-infected monocyte/macrophages cultures, was also observed. It has been shown, therefore, that beneficial or deleterious biomarkers may be present in dengue, regardless of the severity of the disease [44].


2. Thrombocytopenia and dysfunction of platelets in dengue

Reduced proliferative capacity of hematopoietic cells in bone marrow and/or increased destruction of platelets from peripheral blood are two main events associated with thrombocytopenia [45, 46, 47]. Thrombocytopenia occurs when platelet formation (thrombopoiesis) is insufficient to balance physiological or pathological platelet consumption. Thrombocytopenia may occur in patients with either mild or severe cases of dengue infection and are associated in the early days of dengue infection [1]. The WHO guidelines for 2009 reaffirmed that a rapid decline or platelet count below 150,000/mm3 of blood are one of the indicators of clinical dengue worsening. Together, the functional disturbance associated with deregulation of the plasma quinine system is related with the immunopathogenesis of dengue [1, 48, 49].

2.1. Thrombocytopenia induced by bone marrow suppression, lysis of megakaryocytes and/or peripheral destruction of platelets

The kinetic observation of platelet counts in dengue patients showed a mild to moderate decrease in the 3rd to the 7th day, a significant decrease on day 4, reaching normal levels in the 8th or 9th day of the disease [50, 51]. Profound thrombocytopenia (nadir platelet count ≤20,000/mm3) was significantly more likely to detect early warning signs and longer hospital stays, but profound thrombocytopenia was not affected by DENV serotypes, coinfections, and secondary DENV infections [52]. However, a study involving 245 dengue patients showed no relationship between bleeding and platelet count, while 81 nonbleeding patients had a score below 20,000/mm3 [53]. In contrast, another study involving 225 dengue patients suggested that bleeding occurred more frequently in patients with PT [54]. Most clinical guidelines recommend platelet transfusion in patients with dengue who develop severe bleeding or platelet counts below 10–20,000/mm3. However, another study confirms that platelet transfusion does not prevent the development of severe bleeding or shorten coagulation time [55], and in severe dengue disease with hemorrhagic manifestations, the need for intensive care was not significantly associated with PT [52].

Previous published data indicated that DENV can induce thrombocytopenia through bone marrow suppression, lysis of megakaryocytes, and/or peripheral destruction of platelets [56]. Three main mechanisms seem to be involved, although partially explained, such as a direct lesion of progenitor cells by DENV, infected stromal cells, and modification of bone marrow regulation [51]. In fact, studies have shown a hypocellularity in bone marrow and inhibition of megakaryocyte maturation [51, 57]. In vitro studies using an adventitious reticular cell line, which are bone marrow stromal cells, incubated with DENV found DENV antigens in the perinuclear region of these cells [58]. These interactions lead to a modification in the cytokine profile produced in the bone marrow, as in the case of TGF-β capable of inhibiting the differentiation of multipotent stem cells into megakaryocyte precursor cells, leading to inhibition of the cell differentiation process [59, 60]. Another cytokine, the thrombopoietin (TPO), regulates megakaryocytopoiesis and platelet production specifically through the activation of myeloproliferative leukemia virus oncogene (c-MPL), the TPO receptor [61, 62]. When platelet counts fall, circulating levels of TPO increase and may function as a useful indicator of megakaryocytopoiesis in dengue [63, 64]. Recently, authors showed that mice inoculated with recombinant DENV-envelope protein domain III (DENV-EIII)-suppressed megakaryopoiesis of progenitor cells from murine bone marrow and human cord blood in vitro, similarly to those observed with DENV infection. Additional analyses suggested that autophagy impairment and apoptosis are involved in DENV-EIII-mediated suppression of megakaryopoiesis. Thus, these data suggest that, even without viral replication, the binding of DENV-EIII to the cell surface is sufficient to suppress megakaryopoiesis [65].

Although several aspects of the pathogenesis of thrombocytopenia are still not clearly understood, La Russa and Innis in 1995 demonstrated that DENV-induced bone marrow suppression depressed platelet synthesis [58]. In the same year, Wang et al. found that DENV-2 can bind to human platelets in the presence of virus-specific antibody, proposing an immune-mediated clearance of platelets [66]. No infectious model that mimics DHF/DSS has yet been reported until Huang et al. described that the immunocompetent mice intravenous inoculated with DENV-2 developed transient thrombocytopenia and generate IgG class anti-platelet antibody. This was the first evidence of an association between anti-DENV immune response with cross-reactivity to platelets [67]. Falconar gave a strong contribution when identified a highly avid subclone monoclonal antibody MAb 1G5.4-A1-C3 from DENV-2 NS1 and others anti-NS1 MAbs, which in addition of producing hemorrhage in mice, cross-reacted with human fibrinogen, thrombocytes, and endothelial cells, with known epitopes or active sites on human clotting factors and integrin/adhesin proteins present on these cells [68].

Previous study described a strong association between activation status of platelets and their destruction/depletion from circulation in febrile dengue patients [69]. Peripheral destruction of platelets can occur through the direct interaction of the virus in the platelet, as well as indirectly, since the infection leads to the formation of aggregates platelet-endothelial cells and platelets leukocytes or still to the secretion of anti-platelet antibodies and production of factors detrimental to platelets [56]. During dengue infection, cross-reactivity autoantibodies, including antiplatelet antibodies, are generated. In addition, anti-NS1 antibodies belong to the IgM class cross-react with platelets. This last one has the potential for activation of the cascade complement system, leading to the induction of cell lysis and inhibition of platelet aggregation [70, 71]. Notably, high anti-platelet IgM titers were detected in patients with DHF/DSS compared to DF. In accordance with high titers of IgM, serum from DHF/DSS patients causes more platelet lysis than the DF patient serum [71]. Autoantibodies against endothelial cells and blood coagulation molecules have also been described [72]. In fact, molecular mimicry between platelets, endothelial cells, or blood clotting molecules and NS1, prM, and E may explain the cross-reactivity of anti-NS1, anti-prM, or anti-E antibodies between host proteins and proteins. Cross-reactivity antibodies can cause platelet dysfunction, endothelial cell damage, coagulation deficiencies, and activation of macrophages [73]. In addition, it has been recognized that platelet surface P-Selectin (P-CD62) activates integrins and mediates adhesion, aggregation, and secretion of mediators [74].

Among the soluble factors that play a role in the peripheral destruction of platelets, they include platelet-activating factor (PAF) [75], von Willebrand factor (vWF) [76], TNF-α, IL-1β [35], and IL-10 [34].

Platelet apoptosis and phagocytosis associated with high-serum TPO levels were significantly increased in dengue patients during the early stages of convalescence when compared to the late convalescence phase and in healthy volunteers. These results suggest that the abrupt drop in the number of platelets at the beginning of infection is outweighed by TPO-mediated thrombopoiesis [77]. Another study confirmed that platelets from patients exhibited classic signs of the apoptosis intrinsic pathway that include increased phosphatidylserine exposure, mitochondrial depolarization, and activation of caspase-9 and -3 [78].

2.2. Dysfunction of platelets in dengue

Platelet activation is a phenomenon common during physiological dysbalance, such as damage to blood vessels when in contact with components of the subendothelial matrix (collagen and vWF) [79], virus infections such as DENV and human immunodeficiency virus [80], hypothermia [81], diabetes mellitus [82], and arterial thrombosis [83]. Moreover, some agonists involved in platelet activation include adenosine diphosphate (ADP), thromboxane A2 (TXA2), collagen, serotonin, epinephrine, and thrombin [84], in addition to pathogens and toxins [85].

During its activation, the platelets undergo a structural change process, in which the discoid cells undergo modifications in the cytoskeleton, disassembly of a ring of microtubules, resulting in an intermediate spherical shape. Next, actin polymerization and filopodia extension occur, causing the cell to acquire lamellar or dendritic morphology [86]. The major activated platelet receptors on interactions with other cells are glycoprotein GP IIb/IIIa (CD41/CD61) and P-CD62. The CD41/CD61 binds to adhesion proteins that contain the Arginine-Glycine-Asparagine peptide sequence (RGD sequence), thus allowing the pooling and binding of activated platelets to leukocytes and endothelial cells via “bridge molecules,” such as fibrinogen [87]. P-selectin is a glycoprotein stored in platelet α-granules that is translocated to the surface and released in suspension during platelet activation [85]. It is the main adhesion molecule responsible for platelet interaction with monocytes [85, 88, 89, 90], and circulating platelet-monocyte aggregates have been detected in dengue patients [89, 91]. As for the morphological and physiological profile of the platelets exposed to DENV-2, it was observed that there is platelet activation with increased expression of P-CD62 and fibrinogen binding. For morphological changes related to activation, the authors cited membrane architecture alterations, degranulation, the presence of filopodia, and dilation of the open canalicular system in platelets exposed to DENV-2 [92].

The events related to activation are not restricted to changes in morphology, having consequences in several biological functions developed by the platelets. It is also observed exocytosis of constituents of platelet granules, expression of adhesion proteins, and secretion of cytokines and other immunological mediators [93]. Activated platelets secrete mediators stored or synthesized in their granules, which act on several functions. In addition, during plaquetogenesis, megakaryocytes transfer platelet pre-mRNAs, such as tissue factor (TF, inflammatory mediator, and coagulation regulator) pre-mRNA to platelet, are processed to mature mRNA and translated into biologically active TF [94]. In this way, platelets have a complex post-transcriptional repertoire able to translate new proteins, a phenomenon evidenced in response to activation [95, 96]. Multiple pathways lead to platelet activation, including agonists such as collagen, ADP, TXA2, epinephrine, serotonin, and thrombin, through interaction with receptors on platelet surface, leading to release of its granular content, increase of intracellular Ca2+ levels, and activation of the fibrinogen receptor, αIIbβ3 integrin [97, 98, 99, 100]. Studies have been reporting platelet dysfunction in dengue infections. In this context, suppression of platelet aggregation has been shown to occur along with an increased release of beta thromboglobulin (βTG) and Platelet Factor 4 (PF4/CXCL4) during the acute phase of DHF [101]. Assays using mononuclear leukocytes (MNLs) from healthy donors exposed to DENV-1 and 2 release significantly greater amounts of PAF, TXB2, and Prostaglandin D2 (PGD2) than the donor not exposed to any DENV serotypes [102]. Previous data showed that TXB2 plasma levels of DHF patients with shock decreased significantly than those of normal controls and DHF patients without shock patients, supposing that failure or inadequate TXB2 production may eventually lead to shock [103].

In addition to exerting an effector role, platelets influence the production of cytokines by peripheral mononuclear cells. Activated platelets exhibit anti-inflammatory properties related to the CD40 and CD40L interaction, leading to increased IL-10 production and inhibition of TNF-α by monocytes [104]. The authors also verified that the interaction of apoptotic monocytes and platelets regulates the secretion of IL-10 through the recognition of platelet phosphatidylserine. It appears that IL-10 secretion requires only monocyte-platelet contact, but not phagocytosis, indicating that activated and apoptotic platelets aggregate to monocytes during infection [86]. Azeredo et al. found that IL-10 levels were correlated with low platelet counts [34]. Platelets are the major source of TGF-β1 in the human body [105]. One study has shown that circulating levels of TGF-β1 are significantly lower in patients with DHF than in controls [106]. Patients with immune thrombocytopenia have low levels of TGF-β1 in the circulation. However, after therapy to restore normal platelet count, their TGF-β1 levels return to levels found in healthy controls [107].

The innate immune system recognizes infection and changes in cellular homeostasis to initiate responses to clear pathogens and repair tissue damage. Toll-like receptors (TLRs) are part of the innate immune system, key players that modulate the inflammatory response and tumor dynamics. Many investigators have confirmed the expression of TLR1-9 both human and murine platelets [108]. Other major complex involved in these processes is the inflammasome, a multimeric protein complex that activates pro-caspase-1, which then proceeds to cleave multiple substrates including the pro-inflammatory cytokines IL-1β and IL-18 [109]. The presence of the nucleotide-binding domain leucine rich repeat containing protein (NLRP3) inflammasome in platelets activated after infection by DENV has been described, inducing the production of IL-1β by platelets and platelet-derived microparticles of dengue patients [89].


3. Deregulation of the platelets’ role in dengue: Hemostasis, site of virus, and immune cells

3.1. Deregulation between pro-and anticoagulant mechanisms in dengue

Hemostasis is a dynamic process in which physical and biochemical mechanisms promote blood clotting in a fast and regulated way [110]. Platelet adhesion and activation are mediated through the interactions between GP Ib-IX-V receptors with vWF and GP VI with subendothelial collagen [111]. Alternatively, when the vascular endothelium is damaged, collagen sites are exposed, facilitating platelet adhesion at these specific sites. Platelets adhere to molecules in the subendothelial tissues at the lesion site, where they aggregate and interact with leukocytes and endothelial cells, thus initiating the coagulation cascade [112]. The coagulation factors present in the bloodstream are involved in a tightly controlled activation sequence, resulting in the formation of thrombin and subsequently fibrin. These factors circulate as zymogens, which require processing by proteolysis to be activated. According to the new model of blood clotting, it occurs in three overlapping stages: initiation phase, amplification phase, and propagation phase [113].

During acute DENV infection, coagulation and fibrinolysis are activated, leading to coagulation changes and fibrinolytic parameters that may lead to disseminated intravascular coagulation (DIC) [114, 115, 116]. Funahara et al. reported that dengue patients with DIC had decreased platelet counts, transient prolongations of partial thromboplastin time (PTT) and prothrombin time (PT), and decreased levels of fibrinogen, prothrombin activity, factor VIII, antithrombin III, and plasminogen [117]. DIC leads to platelet activation, formation of fibrin, and deposition of small clots in the microcirculation, possibly contributing to organic failure. Notably, the consumption of clotting factors usually leads to paradoxical hemorrhagic disorders due to their consumption [118]. Later, it has been demonstrated that acute DIC that occurs in patients with DHF is associated with increased vascular permeability [117]. Thus, parameters such as platelet count, PTT, and PT present predictive value in the diagnosis of severe dengue [119].

The mechanisms that trigger DIC are mainly related to endothelial lesions and increased circulating TF levels [118]. Several studies have suggested that increased TF expression plays an important role in the pathogenesis of dengue. Huerta-Zepeda et al. showed that DENV regulates levels of protease-activated receptor type 1 (PAR-1) and TF in the activated endothelium [120]. These data are reinforced by the evidence of increased plasma levels of TF in dengue patients, and the expression of TF in monocytes was inversely correlated with platelet counts [121, 122]. Our previous data found that dengue patients with a good outcome showed decreased circulating levels of TF than those with a poor outcome (Severe). Similarly to TF, tissue factor pathway inhibitor (TFPI) levels were significantly lower in patients with a good outcome, but increased TFPI plasma levels were observed in severe patients. We also demonstrated that TF and TFPI levels were significantly higher among patients with hemorrhagic manifestations. In addition, DENV-1 or -2 patients were more likely to have increased levels of TF than DENV-4 patients [123]. Activation of PAR-1 is accompanied by positive regulation of adhesion molecules and production of proinflammatory cytokines [124]. The coagulation enzymes generated in DENV infection can activate PAR-1 receptors, thus increasing the increase of pro-inflammatory cytokines and leukocyte migration. These cytokines, along with coagulation enzymes (and vice versa), perpetuate the inflammatory response, which promotes increased interaction between activated monocytes, activated endothelial cells, and platelets. The result is a convergence of signals that lead to exacerbated expression of TF. Therefore, the coagulation and inflammation processes are closely related and establish a bidirectional relationship mediated by the activation of PARs [125].

Since hemostasis depends on the balance between coagulation and fibrinolysis, Huang et al. evaluated some coagulation parameters (platelet count and PTT) as well as fibrinolytic parameters (tPA and PAI-1) in patients with DHF and DF. Patients with DF show thrombocytopenia, PTT prolongation, and increased tPA levels, indicating coagulation activation and fibrinolysis. However, the parameters used indicated much more severe activation of coagulation and fibrinolysis in patients with DHF. In the convalescent phase, there is an increase in PAI-1 and platelet counts with concomitant decline in tPA levels and normalization of PTT, both in patients with DHF and in DF. According to the authors, the activation of coagulation and fibrinolysis during the acute phase of DENV infection is compensated by the increase of platelets and PAI-1 during the convalescence phase. These results suggest that the degree of activation of coagulation and fibrinolysis induced during dengue infection is associated with the severity of the disease [114].

3.2. Platelets as target cells for DENV replication

Platelets contain receptors related to DENV entry, such as Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) [126]. In vitro infection by DENV induces activation, mitochondrial dysfunction, and platelet apoptosis through mechanisms dependent on the DC-SIGN receptor [127]. A study detected DENV RNA by conventional reverse transcription polymerase chain reaction (RT-PCR) and DENV-like particles by electron microscopy in patients’ platelets [128] and later confirmed the presence of viral antigen in platelets by immunofluorescence and confocal microscopy [129]. It is still unclear whether platelets are involved in the spread of viral infection. Recent data from our group have confirmed the in vitro interaction of DENV with platelets, leading to subsequent morphological modifications characteristic of platelet activation, such as presence of membrane extensions (filopodia), loss of cytoplasmic content and dilation of the membrane system [Azamor and Oliveira submitted]. A study using blood cells from dengue patients and rhesus monkeys experimentally infected revealed DENV antigens present in vesicles of varying sizes and often in nuclear cells like platelets. The DENV RNA was detected in a highly enriched population of rhesus platelet-characteristic CD61+ cells in the acute phase of infection, indicating that the virus may be directly linked to dysfunction and low platelet counts [130]. More recent and for the first time, authors demonstrated in fact that platelets directly bind DENV saturably and produce infectious virus. Interestingly, at 37 and 25°C, platelets replicated the positive sense single-stranded RNA genome of DENV by up to ∼4-fold over 7 days, with production of viral NS1 protein. The infectivity of DENV intrinsically decayed in vitro, which was moderated by platelet-mediated generation of viable progeny. DC-SIGN and heparan sulfate proteoglycan (HSP) were implicated as coreceptors because only the combination of anti-DC-SIGN and low-molecular-weight heparin prevented binding. Thus, expression of antigen encoded by DENV is a novel consideration in the pathogen-induced thrombocytopenia mechanism [131]. Finally, very recent analyze revealed that DENV works as the primary driver of platelet activation and also enters and replicates in platelets but does not result in a productive infection of platelets. Moreover, the DENV-exposed/DENV antigen-positive platelets associate with CD14+CD16+ monocytes may mediate platelet clearance from the circulation [132].

3.3. Platelets as immune cells

Platelets, when interacting physically with leukocytes and endothelial cells, act as a kind of signaling of inflammation and immune response. When stimulated and activated, these cells initiate events, such as aggregation, formation of microparticles and exosomes [133], expression of adhesion proteins and receptors, and exocytosis of constituents present in their granules [76]. Exocytosis of α-dense granules and lysosomes releases cytokines and biological mediators with various immunological and inflammatory functions. In addition to secreting soluble mediators, platelets express receptors involved with the immune defense, such as Fc receptors that are able to recognize IgG, IgE, and IgA classes. These receptors may confer rudimentary antibacterial activities of platelets, such as the secretion of antimicrobial peptides and phagocytosis against direct interaction with bacteria, viruses, protozoa, or helminths. These immunoreceptors influence platelet adhesion activity through the modulation of integrin production [76]. Another set of receptors present on platelets with immunological action is that of TLRs. Among the 10 TLRs identified in humans, six are expressed in platelets, the TLR-1, -2, -4, -6, -8, and -9. TLR-4 has been shown to modulate sepsis and inducer of TNF-α in vivo [134]. TLR-2 modulates IL-1β RNA processing, inducing the production of IFN type 1 and other inflammatory cytokines [135]. The set of inflammatory, hemostatic, angiogenic, and coagulators reactions are multicellular events that include chemotaxis, adhesion, interactions between leukocytes, endothelial cells, and platelets in the walls of blood vessels. Platelets contribute to these interactions through secretion of adhesion proteins and regulation of chemokine synthesis by leukocytes and endothelial cells [136]. Molecules such as IL-1β, PAF, and P-CD62 stand out as the main mediators derived from platelets, able of activating leukocytes [137]. Studies have shown that activated platelets induce increased IL-10 expression and decreased TNF-α by monocytes [101].

Several studies have indicated that DENV infection leads to the activation of endothelial cells, which increase the expression on the surface of the E-CD62 molecule. E-CD62, as well as P-CD62, are adhesion molecules responsible for platelet adhesion to endothelial cells [113, 138]. In addition to the endothelium, P-CD62 is expressed on the surface of activated platelets, promoting their interaction with leukocytes and formation of aggregates between platelets and monocytes and/ or neutrophils in primates [139]. Platelet-monocyte aggregates are also observed in DENV-infected patients, leading to the synthesis of IL-1β, CXCL8/ IL-8, CCL4/ MCP-1, and IL-10 by monocytes [107]. The formation of cell aggregates results in an increase in the inflammatory response in dengue, as well as contributing to the generation of thrombocytopenia both by the physical retention of cells, by lowering the number of circulating cells and by the induction of cell death [140]. In 1992, Butthep et al. showed that platelets, as well as neutrophils and lymphocytes, preferentially bind to endothelial cells exposed to DENV, compared to cells not exposed to DENV. It has been suggested that increased platelet endothelial cell binding may contribute to thrombocytopenia in dengue patients [141]. Protein disulfide isomerase (PDI), an endoplasmic reticular protein, is located on the surface of platelets [142] and is involved in the regulation of integrin-mediated platelet aggregation, since anti-PDI antibodies block platelet adhesion and aggregation [143]. Previous studies have demonstrated that platelet surface PDI can be recognized by anti-NS1 antibodies. Rachman and co-workers observed a similar kinetic profile between anti-NS1 and PDI antibodies [144]. PDI enzyme activity and platelet aggregation were reduced with anti-NS1 action. Amino acid residues 311–330 (P311–330) of NS1 represent an epitope that shares sequence homology with the PDI thiorretoxin domain [145]. In contrast, although the serum of dengue patients inhibits platelet aggregation, there is no correlation between anti-NS1 and PDI with platelet aggregation dysfunction, suggesting that other mechanisms may be involved in the inhibition of platelet aggregation [144, 145]. Platelets are responsible for the maintenance of vascular integrity due to the constitutive release of pro-angiogenic cytokines and growth factors. The α-granule-derived molecules such as angiopoietin-1, α and β-catenins, and PAF bind to specific receptors on the surface of endothelial cells, causing intracellular signaling that stabilizes the intercellular adhesion junctions [146]. Angiopoietins, key molecules of vascular integrity, are also stored in platelets. Both dengue-associated thrombocytopenia and endothelial activation are associated with an imbalance in the ratio of angiopoietin-2: angiopoietin-1 plasmatic. Studies have shown that there is an inverse correlation between angiopoietin-1 and plasma extravasation markers but a direct correlation between angiopoietin-2 and markers of plasma extravasation in patients with DHF/DSS [147]. Hottz et al. demonstrated that DENV-infected patients who showed signs of increased vascular permeability demonstrated a higher percentage of platelets and platelet-derived microparticles (MP) expressing IL-1β and caspase-1 activator compared to patients who had no evidence change in vascular permeability. These results were confirmed in experiments in which platelet-derived MPs exposed to DENV caused an increase in the permeability of endothelial cells that was blocked by IL-1Ra [127].

More recently, proteome analysis related to platelet activating signaling from platelets from dengue patients demonstrated an increase of PAR-4 (F2RL3), G protein subunits (GNA12 and GNA14), and p38 MAPK (MAPK14), in which potentially contributing to increased platelet activation during dengue infection. Moreover, dengue patients had increased P-CD62 surface expression on platelets from patients presenting dengue with warning signs and severe dengue syndromes compared to mild dengue. In agreement, they observed exhaustion of the granule-stored chemokine PF4/CXCL4 in platelets from patients with dengue [148], similarly to another study reported that patients with severe dengue have lower levels of PF4/CXCL4 in plasma when compared to mild dengue patients [149].


4. Conclusion

Platelets are cellular fragments derived from hematopoietic precursors megakaryocytes, primarily associated with coagulation and hemostasis and also with inflammation, immune response, angiogenesis, and extracellular matrix synthesis. In fact, platelets contain several preformed molecules, large amounts of mRNA, and the packaged translational process required to synthesize new biologically active proteins, including growth factors, cytokines, and chemokines. Platelets are one of the major cell populations affected in dengue, once both thrombocytopenia and platelet dysfunction are common manifestations of infection and strongly related to the patient’s clinical outcome. Dysfunction of platelets is implicated in prothrombotic complications associated with severe cases of dengue. Thus, platelets could be considered cells that are active against the anti-DENV immune response, and therefore, thrombocytopenia is a key prognostic factor in the immunopathogenesis of dengue.



DENVdengue virus
DFdengue fever or dengue fever without signs of alarm
DHFdengue hemorrhagic fever
DSSdengue shock syndrome
WHOWorld Health Organization
DFwWSdengue fever with warning signals
ADEantibody-dependent infection
NKsnatural killer cells
pDCplasmacytoid dendritic cells
DCsdendritic cells
IFN-α/βtype I IFNs
IFN-γor IFN-type II
HLAhuman leukocyte antigen
APCsantigen-presenting cells
ICAM-1intracellular adhesion molecule-1
VCAM-1vascular cell adhesion molecule-1
TGF-βtransforming growth factor-beta-receptor
sST2soluble IL-1 receptor type 1 protein
sTRAILtumor necrosis factor-related apoptosis-inducing ligand
PTprofound thrombocytopenia
DENV-EIIIDENV-envelope protein domain III
PAFplatelet-activating factor
vWFvon Willebrand factor
ADPadenosine diphosphate
TXA2thromboxane A2
RGD sequenceArginine-Glycine-Asparagine peptide sequence
TFtissue factor
βTGbeta thromboglobulin
PF4/CXCL4platelet factor 4
PGD2Prostaglandin D2
TLRstoll-like receptors
NLRP3nucleotide-binding domain leucine rich repeat containing protein
DICdisseminated intravascular coagulation
PTTpartial thromboplastin time
PTprothrombin time
PAR-1protease-activated receptor type 1
TFPItissue factor pathway inhibitor
DC-SIGNdendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin
RT-PCRreverse transcription polymerase chain reaction
HSPheparan sulfate proteoglycan
PDIprotein disulfide isomerase


  1. 1. WHO and the Special Programme for Research and Training in Tropical Diseases (TDR). Dengue guidelines for diagnosis, treatment, prevention and control: new edition. (2009, accessed13 February 2017)
  2. 2. Lindenbach BD, Rice CM. Mint: Flaviviridae: the viruses and their replication. In Knipe KM, Howley PM, editors. Fieds Virology. 2001. Philadelphia, PA: Lippicott-Wlikins, pp.991-1041
  3. 3. Kuhn RJ, Zang W, Rossman MG, Pletnev SV, Cover J, Lenches E, Jones CT, Mukhopadhuay S, Chipman PR, Strauss EG, Baker TS, Stauss JH. Mint: Structure of dengue virus: Implications for flavivirus organization, mutation and fusion. Cell. 2002;108(5):717-725
  4. 4. Chambers TJ, Hahn CS, Galler R, Rice CM. Mint: Flavivirus genome organization, expression and replication. Annual Review of Microbiology. 1990;44:649-688
  5. 5. Mukhopadhyay S, Kuhn RJ, Rossmann MG. Mint: A structural perspective of the flavivirus life cycle. Nature Reviews Microbiology. 2005;3(1):13-22
  6. 6. Qi RF, Zhang L, Chi CW. Mint: Biological characteristics of dengue virus and potential targets for drug design. Acta Biochimica et Biophysica Sinica. 2008;40(2):91-101
  7. 7. Gubler DJ. Mint: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends in Microbiology. 2002;10(2):100-103
  8. 8. Bäck AT, Lundkvist Å. Mint: Dengue viruses–an overview. Infection Ecology & Epidemiology. 2013;3:19839
  9. 9. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Mint: Dengue. New England Journal of Medicine. 2012;366(15):1423-1432
  10. 10. Barniol J, Gaczkowski R, Barbato EV, da Cunha RV, Salgado D, Martínez E, Jaenisch T. Mint: Usefulness and applicability of the revised dengue case classification by disease: Multi-centre study in 18 countries. BMC infectious diseases. 2011;11(1):106
  11. 11. Halstead SB, Nimmannitya S, Cohe SN. Mint: Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. The Yale Journal of Biology and Medicine. 1970;42:311-328
  12. 12. Halstead SB, Porterfield JS, O’Rourke EJ. Mint: Enhancement of dengue virus infection in monocytes by flavivirus antisera. The American Journal of Tropical Medicine and Hygiene. 1980;29:638-642
  13. 13. Mongkolsapaya J, Dejnirattisai W, Xu X, et al. Mint: Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature Medicine. 2003;9:921-927
  14. 14. Rothman AL. Mint: Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology. 2011;11(8):532-543
  15. 15. Valdés K, Alvarez M, Pupo M, Vázquez S, Rodríguez R, Guzmán MG. Mint: Human dengue antibodies against structural and nonstructural proteins. Clinical and diagnostic laboratory immunology. 2000;7(5):856-857
  16. 16. Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S. Mint: Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. The American Journal of Tropical Medicine and Hygiene. 1991;44(5):481-493
  17. 17. Rothman AL. Mint: Dengue: Defining protective versus pathologic immunity. Journal of Clinical Investigation. 2004;113(7):946-951
  18. 18. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. Mint: Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005;437(7059):764-769
  19. 19. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, et al. Mint: Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. Journal of Virology. 2009;83(13):6494-6507
  20. 20. Halstead SB. Mint: Neutralization and antibody-dependent enhancement of dengue viruses. Advances in Virus Research 2003;60:421-467
  21. 21. Rivino L. Mint: T cell immunity to dengue virus and implications for vaccine design. Expert Review of Vaccines. 2016;15:443-453
  22. 22. Simmons CP, Dong T, Chau NV, et al. Mint: Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. Journal of Virology. 2005;79:5665-5675
  23. 23. Rivino L, Tan AT, Chia A, et al. Mint: Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity. Journal of Immunology Baltim Md. 2013;191:4010-4019
  24. 24. Malavige GN, Ogg G. Mint: Pathogenesis of severe dengue infection. Ceylon Medical Journal. 2012;57(3):97-100
  25. 25. Samuel CE. Mint: Antiviral actions of interferons. Clinical Microbiology Reviews. 2001;14(4):778-809
  26. 26. Le Bon A, Tough DF. Mint: Links between innate and adaptive immunity via type I interferon. Current Opinion in Immunology. 2002;14(4):432-436
  27. 27. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Jacobs M. Mint: Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. Journal of Virology. 2005;79(9):5414-5420
  28. 28. Ashour J, Laurent-Rolle M., Shi PY, García-Sastre A. Mint: NS5 of dengue virus mediates STAT2 binding and degradation. Journal of Virology. 2009;83(11):5408-5418
  29. 29. Muñoz-Jordán JL1, Laurent-Rolle M, Ashour J, Martínez-Sobrido L, Ashok M, Lipkin WI, García-Sastre A. Mint: Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. Journal of Virology. 2005;79(13):8004-8013
  30. 30. Gandini M, Gras C, Azeredo EL, de Oliveira Pinto LM., Smith N, Despres P, Herbeuval JP. Mint: Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells In vitro and In vivo. PLoS Neglected Tropical Diseases. 2013;7(6):e2257
  31. 31. Commins SP, Borish L, Steinke JW. Mint: Immunologic messenger molecules: Cytokines, interferons, and chemokines. Journal of Allergy and Clinical Immunology. 2010;125(2):S53-S72
  32. 32. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA. Mint: Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. Journal of Clinical Investigation. 1991;88(5):1473
  33. 33. Dewi BE, Takasaki T, Kurane I. Mint: In vitro assessment of human endothelial cell permeability: Effects of inflammatory cytokines and dengue virus infection. Journal of Virological Methods. 2004;121(2):171-180
  34. 34. Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, Kubelka CF. Mint: Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology. 2001;204(4):494-507
  35. 35. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Kubelka CF. Mint: Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infectious Diseases. 2008;8(1):86
  36. 36. Juffrie M, Meer GV, Hack CE, Haasnoot K, Veerman AJ, Thijs LG. Mint: Inflammatory mediators in dengue virus infection in children: Interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. The American Journal of Tropical Medicine and Hygiene. 2001;65(1):70-75
  37. 37. Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Mint: Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunology & Medical Microbiology. 2001;30(3):229-233
  38. 38. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, Chen LC, Huang JH, Lam TM, Liu CC, Halstead SB. Mint: Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. The Journal of Infectious Diseases. 2004;189(2):221-232
  39. 39. Raghupathy R, Chaturvedi UC, Al-Sayer H, Elbishbishi EA, Agarwal R, Nagar R, Kapoor S, Misra A, Mathur A, Nusrat H, Azizieh F, Khan MA, Mustafa AS. Mint: Elevated levels of IL-8 in dengue hemorrhagic fever. Journal of medical virology. 1998;56(3):280-285
  40. 40. Restrepo BN, Isaza DM, Salazar CL, Ramírez R, Ospina M, Alvarez LG. Mint: Serum levels of interleukin-6, tumor necrosis factor-alpha and interferon-gama in infants with and without dengue. Revista da Sociedade Brasileira de Medicina Tropical. 2008;41(1):6-10
  41. 41. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Mint: Cytokine cascade in dengue hemorrhagic fever: Implications for pathogenesis. FEMS Immunology & Medical Microbiology. 2000;28(3):183-188
  42. 42. Miller JL, M deWet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S. Mint: The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathogens. 2008;4(2):e17
  43. 43. Libraty DH, Endy TP, Houng HSH, Green S, Kalayanarooj S, Suntayakorn S, Rothman AL. Mint: Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. Journal of Infectious Diseases. 2002;185(9):1213-1221
  44. 44. Arias J, Valero N, Mosquera J, Montiel M, Reyes E, Larreal Y, Alvarez-Mon M. Mint: Increased expression of cytokines, soluble cytokine receptors, soluble apoptosis ligand and apoptosis in dengue. Virology 2014;452:42-51
  45. 45. Basu A, Jain P, Gangodkar SV, Shetty S, Ghosh K. Mint: Dengue 2 virus inhibits in vitro megakaryocytic colony formation and induces apoptosis in thrombopoietin-inducible megakaryocytic differentiation from cord blood CD34+ cells. FEMS Immunology & Medical Microbiology. 2008;53:46-51
  46. 46. Nakao S, Lai C-J, Young NS. Mint: Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood. 1989;74:1235-1240
  47. 47. Azeredo EL de, Monteiro RQ, De-Oliveira pinto LM. Mint: Thrombocytopenia in dengue: Interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators. Mediators of Inflammation. 2015;3:138-142
  48. 48. WHO. WHO Recommended Surveillance Standards. Second edition. Global Alert and Respose - Disease Outbreak Reported. 2002. 116
  49. 49. Jayashree K, Manasa GC, Pallavi P, Manjunath GV. Mint: Evaluation of platelets as predictive parameters in dengue fever. Indian Journal of Hematology and Blood Transfusion. 2011;27(3):127-130
  50. 50. Mitrakul C. Mint: Bleeding problem in dengue haemorrhagic fever: Platelets and coagulation changes. Southeast Asian Journal of Tropical Medicine and Public Health. 1987;18(3):407-412
  51. 51. Srichaikul T, Nimmannitya S. Mint: Haematology in dengue and dengue haemorrhagic fever. Best Practice & Research Clinical Haematology. 2000;13(2):261-276
  52. 52. Dhanoa A, Rajasekaram G, Hassan SS, Ramadas A, Azreen Adnan NA, Lau CF, Chan TS, Ngim CF. Mint: Risk factors and clinical outcome of profound thrombocytopenia in adult patients with DENV infections. Platelets. 2017;28(7):724-727
  53. 53. Chaudhary R, Khetan D, Sinha S, Sinha P, Sonker A, Pandey P, Das SS, Agarwal P, Ray V. Mint: Transfusion support to dengue patients in a hospital based blood transfusion service in north India. Transfusion and Apheresis Science. 2006;35(3):239-244
  54. 54. Makroo RN, Raina V, Kumar P, Kanth RK. Mint: Role of platelet transfusion in the management of dengue patients in a tertiary care hospital. Asian Journal of Transfusion Science. 2007;1(1):4
  55. 55. Khan Assir MZ, Kamran U, Ahmad HI, Bashir S, Mansoor H, Anees SB, Akram J. Mint: Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. Transfus Med Hemother. 2013;40(5):362-368
  56. 56. Hottz E, Tolley ND, Zimmerman GA, Weyrich AS, Bozza FA. Mint: Platelets in dengue infection. Drug Discovery Today: Disease Mechanisms. 2011;8(1):e33-e38
  57. 57. Kho LK, Wulur H, Himawan T. Mint: Blood and bone marrow changes in dengue haemorrhagic fever. Paediatrica Indonesiana. 1972;12(1):31
  58. 58. La Russa VF, Innis BL. Mint: Mechanisms of dengue virus-induced bone marrow suppression. Baillière's Clinical Haematology. 1995;8(1):249-270
  59. 59. Klinger MH, Jelkmann W. Mint: Review: Role of blood platelets in infection and inflammation. Journal of Interferon & Cytokine Research. 2002;22(9):913-922
  60. 60. Badalucco S, Di Buduo CA, Campanelli R, Pallotta I, Catarsi P, Rosti V, Kaplan DL, Barosi G, Massa M, Balduini A. Mint: Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica and Haematology. 2013
  61. 61. de Sauvage FJ1, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, et al. Mint: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533-538
  62. 62. Gurney AL, Carver-Moore K, de Sauvage F, Moore MW. Mint: Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265(5177):1445-1447
  63. 63. Putintseva E, Vega G, Fernandez L. Mint: Alterations in thrombopoiesis in patients with thrombocytopenia produced by dengue hemorrhagic fever. Nouvelle Revue Francaise D'Hematologie. 1985;28(5):269-273
  64. 64. Matondang AV, Widodo D, Zulkarnain I, Rengganis I, Trihandini I, Inada K, Endo S. Mint: The correlation between thrombopoietin and platelet count in adult dengue viral infection patients. Acta Medica Indonesiana. 2004;36(2):62-69
  65. 65. Lin GL, Chang HH, Lien TS, Chen PK, Chan H, Su MT, Liao CY, Sun DS. Mint: Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis. Virulence. 2017;8(8):1719-1731
  66. 66. Wang S, He R, Patarapotikul J, Innis BL, AR. Mint: Antibody-enhanced binding of dengue-2 virus to human platelets. Virology. 1995;213(1):254-257
  67. 67. Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY. Mint: Manifestation of thrombocytopenia in dengue-2-virus-infected mice. The Journal of General Virology. 2000;81(Pt 9):2177-2182
  68. 68. Falconar AK. Mint: The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Archives of Virology. 1997;142(5):897-916
  69. 69. Ojha A, Nandi D, Batra H, Singhal R, Annarapu GK, Bhattacharyya S, Seth T, Dar L, Medigeshi GR, Vrati S, Vikram NK, Guchhait P. Platelet activation determines the severity of thrombocytopenia in dengue infection. Scientific Reports. 2017;7:41697
  70. 70. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS. Mint: Autoimmunity in dengue pathogenesis. Journal of the Formosan Medical Association. 2013;112(1):3-11
  71. 71. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS. Mint: Generation of IgM anti-platelet autoantibody in dengue patients. Journal of Medical Virology. 2001;63(2):143-149
  72. 72. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS. Mint: Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. Journal of Medical Virology. 2003;69(1):82-90
  73. 73. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY. Mint: Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Experimental Biology and Medicine. 2011;236(5):515-523
  74. 74. Chen M, Geng JG. Mint: P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Archivum Immunologiae et Therapiae Experimentalis. 2006;54(2):75-84
  75. 75. Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, Kroon EG, Sachs D, Cunha FQ, Bukin E, Atrasheuskaya A, Ignatyev G, Teixeira MM. Mint: Essential role of platelet activating factor receptor in the pathogenesis of dengue virus infection. PNAS. 2009;106(33):14138-14143
  76. 76. Basuki PS. Mint: A glance at the von Willebrand factor in dengue virus infection. Southeast Asian J Trop Med Public Health. 2003;34(3):559-563
  77. 77. Alonzo MT, Lacuesta TL, Dimaano EM, Kurosu T, Suarez LA, Mapua CA, Akeda Y, Matias RR, Kuter DJ, Nagata S, Natividad FF, Oishi K. Mint: Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. Journal of Infectious Diseases. 2012;205(8):1321-1329
  78. 78. Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza MT, Bozza PT. Mint: Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood. 2013;122(20):3405-3414
  79. 79. Cimmino G, Golino P. Mint: Platelet biology and receptor pathways. Journal of Cardiovascular Translational Research. 2013;6(3):299-309
  80. 80. Torre D, Pugliese A. Mint: Platelets and HIV-1 infection: Old and new aspects. Current HIV Research. 2008;6:411-418
  81. 81. Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Mint: Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thrombosis and Haemostasis. 1994;71(5):633-640
  82. 82. Davı̀ G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Patrono C. Mint: In vivo formation of 8-Iso-prostaglandin F2α and platelet activation in diabetes mellitus effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99(2):224-229
  83. 83. Davì G, Patrono C. Mint: Platelet activation and atherothrombosis. New England Journal of Medicine. 2007;357(24):2482-2494
  84. 84. Jennings LK. Mint: Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and Haemostasis. 2009;102(2):248-257
  85. 85. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: Versatile effector cells in hemostasis, inflammation, and the immune continuum. Seminars in Immunopathology. 2012;34:5-30
  86. 86. Jurk K, Kehrel BE. Mint: Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31(4):381-92
  87. 87. Calvete JJ, Henschen A, González-Rodríguez J. Mint: Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the beta-subunits of the integrin family. The Biochemical Journal. 1991;274:63-71
  88. 88. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Mint: Activated platelets signal chemokine synthesis by human monocytes. The Journal of Clinical Investigation. 1996;97:1525-1534
  89. 89. Hottz ED, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Assis EF, Vals-de-Souza R, Castro-Faria-Neto HC, Weyrich AS, Zimmerman GA, Bozza FA, Bozza PT. Mint: Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue. Journal of Immunology 2014;193:1864-1872
  90. 90. Larsen E, Celi U, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B. Mint: PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59:305-312
  91. 91. Tsai JJ, Jen YH, Chang JS, Hsiao HM, Noisakran S, Perng GC. Mint: Frequency alterations in key innate immune cell components in the peripheral blood of dengue patients detected by FACS analysis. Journal of Innate Immunity. 2011;3:530-540
  92. 92. Ghosh K, Gangodkar S, Jain P, Shetty S, Ramjee S, Poddar P, Basu A. Mint: Imaging the interaction between dengue 2 virus and human blood platelets using atomic force and electron microscopy. Journal of electron microscopy. 2008;57(3):113-118
  93. 93. Shi G, Morrell CN. Mint: Platelets as initiators and mediators of inflammation at the vessel wall. Thrombosis research. 2011;127(5):387-390
  94. 94. Rondina MT, Schwertz H, Harris ES, Kraemer BF, Campbell RA, Mackman N, Grissom CK, Weyrich AS, Zimmerman GA. Mint: The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. Journal of Thrombosis and Haemostasis. 2011;9(4):748-58
  95. 95. Zimmerman GA, Weyrich AS. Mint: Signal-dependent protein synthesis by activated platelets new pathways to altered phenotype and function. Arteriosclerosis, thrombosis, and vascular biology. 2008;28(3):s17-s24
  96. 96. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Mint: Protein synthesis by platelets: historical and new perspectives. Journal of Thrombosis and Haemostasis. 2009;7(2):241-246
  97. 97. Brass LF. Mint: Thrombin and platelet activation. Chest. 2003;124:18S-25S
  98. 98. Davi G, Patrono C. Mint: Platelet activation and atherothrombosis. The New England Journal of Medicine. 2007;357:2482-2494
  99. 99. Offermanns S. Mint: Activation of platelet function through G protein-coupled receptors. Circulation Research. 2006;99:1293-1304
  100. 100. Li Z, Delaney MK, O’Brien KA, Du X. Mint: Signaling during platelet adhesion and activation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:2341-2349
  101. 101. Srichaikul T, Nimmannitya S, Sripaisarn T, Kamolsilpa M, Pulgate C. Mint: Platelet function during the acute phase of dengue hemorrhagic fever. The Southeast Asian Journal of Tropical Medicine and Public Health. 1989;20(1):19-25
  102. 102. Yang KD, Lee CS, Hwang KP, Chu ML, Shaio MF. Mint: A model to study cytokine profiles in primary and heterologously secondary Dengue-2 virus infections. Acta virologica. 1995;39(1):19-21
  103. 103. Preeyasombat C, Treepongkaruna S, Sriphrapradang A, Choubtum L. Mint: The role of prostacyclin (PGI2) and thromboxane A2 (TXA2) in pathogenesis of dengue hemorrhagic fever (DHF). Journal of the Medical Association of Thailand. 1999;82:S16-S21
  104. 104. Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Mint: Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes. The Journal of Immunology. 2013;191(8):4059-4067
  105. 105. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Mint: Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. Journal of Biological Chemistry. 1983;258(11):7155-7160
  106. 106. Djamiatun K, Faradz SM, Setiati TE, Netea MG, van der Ven AJ, Dolmans WM. Mint: Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-Β1 in children with dengue haemorrhagic fever in Indonesia. Journal of Tropical Pediatrics. 2011
  107. 107. Andersson PO, Olsson A, Wadenvik H. Mint: Reduced transforming growth factor-β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. British Journal of Haematology. 2002;116(4):862-867
  108. 108. Janeway Jr CA, Medzhitov R. Mint: Innate immune recognition. Annual Review of Immunology. 2002;20(1):197-216
  109. 109. Place DE, Kanneganti TD. Mint: Recent advances in inflammasome biology. Current Opinion in Immunology. 2017;50:32-38
  110. 110. Qu Z, Chaikof EL. Mint: Interface between hemostasis and adaptive immunity. Current Opinion in Immunology. 2010;22(5):634-642
  111. 111. Rumbaut RE, Thiagarajan P. Mint: Platelet-vessel wall interactions in hemostasis and thrombosis. Synthesis Lectures on Integrated Systems Physiology: From Molecule to Function. 2010;2(1):1-75
  112. 112. Furie B, Furie BC. Mint: Mechanisms of thrombus formation. New England Journal of Medicine. 2008;359(9):938-949
  113. 113. Hoffman M. Mint: A cell-based model of coagulation and the role of factor VIIa. Blood Reviews. 2003;17:S1-S5
  114. 114. Huang YH, Liu CC, Wang ST, Lei HY, Liu HS, Lin YS, Yeh TM. Mint: Activation of coagulation and fibrinolysis during dengue virus infection. Journal of medical virology. 2001;63(3):247-251
  115. 115. Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Mint: Activation of endothelial cells, coagulation and fibrinolysis in children with dengue virus infection. Thrombosis and Haemostasis. 2007;97(4):627-634
  116. 116. Wills B, Tran VN, Nguyen TH, Truong TT, Tran TN, Nguyen MD, Tran VD, Nguyen VV, Dinh TT, Farrar J. Mint: Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding. The American Journal of Tropical Medicine and Hygiene. 2009;81(4):638-644
  117. 117. Funahara Y, Sumarmo, Shirahata A, Setiabudy-Dharma R. Mint: DHF characterized by acute type DIC with increased vascular permeability. The Southeast Asian Journal of Tropical Medicine and Public Health 1987;18(3):346-350
  118. 118. Bick RL. Mint: Disseminated intravascular coagulation: A review of etiology, pathophysiology, diagnosis, and management: Guidelines for care. Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2002;8(1):1-31
  119. 119. Liu JW, Lee IK, Wang L, Chen RF, Yang KD. The usefulness of clinical-practice-based laboratory data in facilitating the diagnosis of dengue illness. BioMed Research International. 2013;2013:198797
  120. 120. Huerta-Zepeda A, Cabello-Gutiérrez C, Cime-Castillo J, Monroy-Martínez V, Manjarrez-Zavala ME, Gutiérrez-Rodríguez M, Izaguirre R, Ruiz-Ordaz BH. Mint: Crosstalk between coagulation and inflammation during dengue virus infection. Thombosis and Haemostasis-Stuttgart. 2008;99(5):936
  121. 121. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, Chau NV, Chambers M, Stepniewska K, Farrar JJ, Levin M. Mint: Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with dengue shock syndrome. Clinical infectious diseases. 2002;35(3):277-285
  122. 122. de Azeredo EL, Kubelka CF, Alburquerque LM, Barbosa LS, Damasco PV, Avila CA, Motta-Castro AR, da Cunha RV, Monteiro RQ. Tissue factor expression on monocytes from patients with severe dengue fever. Blood Cells, Molecules & Diseases. 2010;45(4):334-335
  123. 123. Leal de Azeredo E, Solórzano VE, de Oliveira DB, Marinho CF, de Souza LJ, da Cunha RV, Damasco PV, Kubelka CF, de-Oliveira-Pinto LM. Mint: Increased circulating procoagulant and anticoagulant factors as TF and TFPI according to severity or infecting serotypes in human dengue infection. Microbes and Infection. 2017;19(1):62-68
  124. 124. Levi M, van der Poll T, Büller HR. Mint: Bidirectional relation between inflammation and coagulation. Circulation. 2004;109(22):2698-2704
  125. 125. Ruf W. Mint: Protease-activated receptor signaling in the regulation of inflammation. Critical Care Medicine. 2004;32(5):S287-S292
  126. 126. Boukour S, Massé JM, Bénit L, Dubart-Kupperschmitt A, Cramer EM. Mint: Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes. Journal of Thrombosis and Haemostasis. 2006;4(2):426-435
  127. 127. Hottz ED, Oliveira MF, Nunes PC, Nogueira RMR, Valls-de-Souza R, Da Poian AT, Mint BFA. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. Journal of Thrombosis and Haemostasis. 2013;11(5):951-962
  128. 128. Noisakran S, Gibbons RV, Songprakhon P, Jairungsri A, Ajariyakhajorn C, Nisalak A, Jarman RG, Malasit P, Chokephaibulkit K, Perng GC. Mint: Detection of dengue virus in platelets isolated from dengue patients. The Southeast Asian Journal of Tropical Medicine and Public Health. 2009;40(2):253-262
  129. 129. Noisakran S, Chokephaibulkit K, Songprakhon P, Onlamoon N, Hsiao HM, Villinger F, Perng GC. Mint: A re-evaluation of the mechanisms leading to dengue Hemorrhagic fever. Annals of the New York Academy of Sciences. 2009;1171(s1):E24-E35
  130. 130. Noisakran S, Onlamoon N, Hsiao HM, Clark KB, Villinger F, Ansari AA, Perng GC. Infection of bone marrow cells by dengue virus in vivo. Experimental Hematology. 2012;40(3):250-259
  131. 131. Simon AY, Sutherland MR, Pryzdial EL. Dengue virus binding and replication by platelets. Blood. 2015;126(3):378-385
  132. 132. Kar M, Singla M, Chandele A, Kabra SK, Lodha R, Medigeshi GR. Dengue Virus Entry and Replication Does Not Lead to Productive Infection in Platelets. Open Forum Infectious Diseases. 2017;4(2):ofx051
  133. 133. Aatonen MT, Öhman T, Nyman TA, Laitinen S, Grönholm M, Siljande PRM. Isolation and characterization of platelet-derived extracellular vesicles. Journal of Extracellular Vesicles. 2014;3
  134. 134. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Mint SJW. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood. 2006;107(2):637-641
  135. 135. Shashkin PN, Brown GT, Ghosh A, Marathe GK, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. The Journal of Immunology. 2008;181(5):3495-3502
  136. 136. Carestia A, Kaufman T, Schattner M. Platelets: New Bricks in the Building of Neutrophil Extracellular Traps. Frontiers in Immunology. 2016;7(271)
  137. 137. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, Mint KNJ. Circulating platelet–neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. British Journal of Haematology. 1999;106(2):391-399
  138. 138. Krishnamurti C, Peat RA, Cutting MA, Mint RSW. Platelet adhesion to dengue-2 virus-infected endothelial cells. The American Journal of Tropical Medicine and Hygiene. 2002;66(4):435-441
  139. 139. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, Perng GC. Mint: Dengue virus–induced hemorrhage in a nonhuman primate model. Blood. 2010;115(9):1823-1834
  140. 140. Andrews RK, Arthur JF, Gardiner EE. Mint: Neutrophil extracellular traps (NETs) and the role of platelets in infection. Thrombosis and Haemostasis. 2014;112(4):659-665
  141. 141. Butthep P, Bunyaratvej A, Bhamarapravati N. Mint: Dengue virus and endothelial cell: A related phenomenon to thrombocytopenia and granulocytopenia in dengue hemorrhagic fever. The Southeast Asian Journal of Tropical Medicine and Public Health. 1992;24:246-249
  142. 142. Chen K, Detwiler TC, Essex DW. Mint: Characterization of protein disulphide isomerase released from activated platelets. British Journal of Haematology. 1995;90(2):425-431
  143. 143. Essex DW, Li M. Protein disulphide isomerase mediates platelet aggregation and secretion. British Journal of Haematology. 1999;104(3):448-454
  144. 144. Rachman A, Harahap AR, Widhyasih RM. Mint: The role of anti-dengue virus NS-1 and anti-protein disulfide isomerase antibodies on platelet aggregation in secondary dengue infection. Acta Medica Indonesiana. 2013;45(1):44-48
  145. 145. Cheng HJ, Lei HY, Lin CF, Luo YH, Wan SW, Liu HS, Yeh TM, Lin YS. Mint: Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Molecular Immunology. 2009;47(2):398-406
  146. 146. Nachman RL, Rafii S. Mint: Platelets, petechiae, and preservation of the vascular wall. New England Journal of Medicine. 2008;359(12):1261-1270
  147. 147. Michels M, van der Ven AJ, Djamiatun K, Fijnheer R, de Groot PG, Griffioen AW, Sebastian S, Faradz SM, de Mastro Q. Mint: Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. The American Journal of Tropical Medicine and Hygiene. 2012;87(5):943-946
  148. 148. Trugilho MRO, Hottz ED, Brunoro GVF, Teixeira-Ferreira A, Carvalho PC, Salazar GA, Zimmerman GA, Bozza FA, Bozza PT, Perales J. Mint: Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue. PLoS Pathogens 2017;13(5):e1006385
  149. 149. Fragnoud R, Flamand M, Reynier F, Buchy P, Duong V, Pachot A, Paranhos-Baccala G, Bedin F. Mint: Differential proteomic analysis of virus-enriched fractions obtained from plasma pools of patients with dengue fever or severe dengue. BMC Infectious Diseases. 2015;15:518

Written By

Tamiris Azamor da Costa Barros and Luzia Maria de-Oliveira-Pinto

Submitted: May 12th, 2017 Reviewed: December 12th, 2017 Published: March 7th, 2018